Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 1065-1072

  Bhavnani, Sujata M ^a,b   Rubino, Christopher M ^a,b   Hammel, Jeffrey P ^a   Forrest, Alan ^a,b   Dartois, Nathalie ^c   Cooper, C Angel ^c   Korth Bradley, Joan ^c   Ambrose, Paul G ^a,b  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOGLYCOSIDE; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; TIGECYCLINE; VANCOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; VENTILATOR ASSOCIATED PNEUMONIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CROSS INFECTION; DOUBLE-BLIND METHOD; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856076038     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01615-10     Document Type: Article

References (19)

1. Albert A, Anderson JA. 1984. On the existence of maximum-likelihood estimates in logistic regression models. Biometrika 77:1-10.
2. Al-Muhairi SA, Zoubeidi TA, Ellis ME, Safa WF, Joseph J. 2006. Risk factors predicting outcome in patients with pneumonia in Al-Ain, United Arab Emirates. Saudi Med. J. 27:1044-1048. (Pubitemid 44612781)
3. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. 2010. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin. Infect. Dis. 51(Supp. 1):S103-S110.
4. Ambrose PG. 2008. Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design. Clin. Infect. Dis. 47:S225-S231.
5. Anonymous. 2009. FDA asks for more information before sanctioning J &J PRD's drug for hospital-acquired pneumonia. Genet. Engin. Biotechnol. News http://www.genengnews.com/news/bnitem.aspx?name=40760576&source= genwire.
6. Anonymous. 2009. FDA raps J &J's knuckles over clinical trials of ceftobiprole antibiotic. Genet. Engin. Biotechnol. News http://www.genengnews. com/news/bnitem.aspx?name=60851393.
7. Boucher HW, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
8. Craig WA. 2007. Pharmacodynamics of antimicrobials: general concepts and applications, p. 1-19. In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed.), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed. Informa Healthcare USA, Inc., New York, NY.
9. Freire AT, et al. 2010. Comparison of tigecycline with imipenem/cilistatin for the treatment of hospital-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 68:140-151.
10. Hosmer DW, Lemeshow S. 1989. Applied logistic regression. Wiley, New York, NY.
11. Joung MK, et al. 2010. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J. Infect. 61:212-218.
12. Kollef KE, Reichley RM, Micek ST, Kollef MH. 2008. The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest 133:363-369. (Pubitemid 351272393)
13. Kollef MH. 2005. What is ventilator-associated pneumonia and why is it important? Respir. Care 50:714-721. (Pubitemid 46187577)
14. Meagher AK, et al. 2007. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob. Agents Chemother. 51:1939-1945. (Pubitemid 46903077)
15. Passarell JA, et al. 2008. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob. Agents Chemother. 52:204-210.
16. R Development Core Team. 2006. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
17. Rubino CM, et al. 2010. Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Antimicrob. Agents Chemother. 54:5180-5186.
18. Wyeth Pharmaceuticals Inc. 2011. Tygacil (tigecycline) for injection. Wyeth Pharmaceuticals Inc., Philadelphia, PA.
19. Zhou Q, et al. 2011. Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections. Drugs Aging 28:903-912.